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ABSTRACT 
 
Aim: The HMG-CoA reductase inhibitor, simvastatin (SV), is known to be extensively 
metabolised by CYP3A4 in humans. However, clinical studies have suggested a possible 
involvement of the polymorphic enzyme CYP2D6 in the metabolism of one or more of the 
active metabolites of the SV. The present in vitro study was conducted to investigate the role 
of CYP2D6 in SV metabolism, and in particular clarify whether any of the SV metabolites are 
possible substrates for CYP2D6.  
 
Methods:  Two different strategies were used. First, SV was incubated with human liver 
microsomes (HLM) in absence and presence of potent CYP3A4 or CYP2D6 inhibitors. Then, 
incubation of SV was performed with microsomes of recombinant CYP3A4 and CYP2D6 
(T5-3A4 and T5-2D6). SV was first incubated with T5-3A4 microsomes, then, the remaining 
SV and metabolites produced by T5-3A4 were subjected to metabolism with T5-2D6 
microsomes. SV and metabolites were analysed by a high-performance liquid 
chromatography-mass spectrometry (HPLC-MS) method, developed in the present work.  
 
Results: Upon incubation of SV with HLM, five possible SV related metabolites were 
detected. All of the deduced metabolites were found to increase with incubation time. The 
metabolites together represented four different phase I metabolic modifications of SV, giving 
rise to the metabolites 6´-CH2OH-SV (I), 3´-OH-SV (II), 6´-exomethylene-SV (III), 3´-OH-
6´-CH2OH-SV (IV) and 6´-COOH-SV (V). Inhibition studies and studies with recombinant 
CYP microsomes showed that CYP3A4 was involved in all these reactions. CYP2D6 was 
apparently not catalysing any of the reactions, but a clear trend of unspecific accumulation of 
SV and all measured metabolites in presence of the CYP2D6 inhibitor quinidine indicated 
that CYP2D6 might be responsible for a metabolic reaction not detected in this work. This 
was supported by an unspecific decline of SV and the metabolites produced by T5-3A4 
following T5-2D6 incubation, which could not be reflected as new chromatographic peaks 
after T5-D6 incubations. 
 
Conclusion: The present in vitro study suggests that CYP2D6 is involved in metabolism of 
SV and several phase I metabolites with pharmacological activity (in their acid form). 
However, the potential in vivo importance of CYP2D6 involvement needs to be evaluated in a 
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study where pharmacokinetic measurements of SV and metabolites are investigated in 
relation to CYP2D6 phenotype. Attempts should also be made to identify the metabolites 
apparently produced via CYP2D6. 
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ABBREVIATIONS 
 
API   Atmospheric pressure ionisation 
CHD   Coronary heart disease 
CI   Chemical ionisation 
CYP   Cytochrome P450 
EM   Extensive metabolisers 
ES   Electrospray 
ESI   Electrospray ionisation 
HEM   Heterozygous extensive metabolisers 
HLM   Humane liver microsomes 
HMG-CoA  3-Hydroxy-3-methylglutaryl coenzyme A 
HPLC   High performance liquid chromatography 
I.S.   Internal standard 
LDL   Low-density lipoprotein 
LV   Lovastatin 
M1   Desacetyldiltiazem 
M2   N-demethyldiltiazem 
M4   O-demethyldiltiazem 
M6   N, O-didemethyldiltiazem 
MS    Mass spectrometry 
m/z   Mass-to-charge ratio  
NADPH  Nicotinamid adenine dinucleotide phosphate 
PM   Poor metabolisers 
SD   Standard deviation 
SV   Simvastatin 
SVA   Simvastatin acid 
T5-3A4  Recombinant human liver cells transfected with CYP3A4   
T5-2D6  Recombinant human liver cells transfected with CYP2D6   
UM   Ultra rapid metabolisers 
V/V   Volume/volume 
Q.C   Quality control  
I   6´-CH2OH-simvastatin 
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II   3´-OH-simvastatin 
III   6´-exomethylene simvastatin 
IV   3´-OH-6´-CH2OH-simvastatin 
V   6´-COOH-simvastatin 
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1. INTRODUCTION 
 
1.1 AIM OF STUDY 
 
The HMG-CoA reductase inhibitor, simvastatin (SV), is known to be extensively metabolised 
by CYP3A4 in humans [1]. It has been speculated that the polymorphic enzyme CYP2D6 
could be involved in the metabolism of active SV metabolites based on an apparent 
association of CYP2D6 phenotype and clinical effect [2, 3].  Thus, the aim of this study was 
to investigate the possible involvement of CYP2D6 in SV metabolism by performing in vitro 
experiments using human liver microsomes (HLM) and recombinant CYP microsomes. 
 
1.2 DRUG METABOLISM 
 
Drug metabolism refers to the process by which drugs are biochemically modified to facilitate 
their excretion from the body. Lipophilic drugs are converted into more hydrophilic, usually 
less active or inactive metabolites. However, this biotransformation can also generate 
metabolites with potent biological activity or even toxic properties. The enzyme systems 
involved in metabolism of drugs are primarily localised in the liver, but other tissues and 
organs like the mucosa of the intestine, kidneys, lungs, white blood cells and skin have 
metabolic capacity as well [4]. Drug metabolic reactions may be divided into two categories; 
phase I and phase II. Phase I involves modifications such as oxidation, dealkylation, 
hydrolysis and reduction, while phase II metabolism involves conjugation of glucuronide, 
glycin or sulphate to the parent drug or its phase I metabolites [5]. 
 
1.2.1 CYTOCHROME P450 MONOOXYGENASE SYSTEM  
The most important enzyme system involved in drug metabolism is the cytochrome P450 
(CYP) enzyme system of microsomal mixed function oxidases. This system is involved in the 
metabolism of 50-60 % of all clinically used drugs as well as being important in the 
metabolism of many xenobiotic chemicals [6]. The CYP enzymes are primarily located in the 
endoplasmatic reticulum of liver cells (Fig. 1-1), but some are also found in the intestinal 
mucosa [7]. 
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Fig. 1-1: Cellular localization of the cytochrome P450 enzymes [8]. 
 
The CYP system comprises a superfamily of enzymes.  A nomenclature system was 
introduced in 1987 [9], which classifies enzymes into families and subfamilies according to 
their overlaps in amino acid sequence. Sequence homology greater than 40 % assembles 
enzymes into families (indicated by an Arabic number, e.g. CYP3), while enzymes within 
subfamilies share greater than 55% homology (indicated by the capital letter following the 
family designation, e.g. CYP3A). The final Arabic number following the subfamily 
designation indicates the individual isoforms within each subfamily (e.g. CYP3A4) [10]. In 
humans, about 60 different CYP enzymes have been described [11], but only a few are 
important in drug metabolism. The CYP1, CYP2, and CYP3-families are importantly 
involved in drug metabolism and their representatives in humans are CYP2C9, CYP2C19, 
CYP2D6, CYP1A2, and CYP3A4. CYP3A4 is by far the most important by being involved in 
approximately  50 % of all CYP mediated drug metabolism, whereas 20 % are substrates for 
CYP2D6 [4, 6, 12]. 
 
1.2.2 CYP ENZYMES AND INTERINDIVIDUAL VARIABILITY 
Despite the expansive knowledge on the field genetics and drug metabolism the past decade, 
it is still difficult to predict the outcome of drug therapy for a given individual. The drug level 
in plasma can vary 1000-fold between two persons having the same weight and drug dosage 
[13]. Such variation may arise from a range of environmental factors affecting drug 
metabolising capacity (dietary habits, age, sex, cigarette smoking, drug interactions and 
disease states). More important is probably the genetic diversity amongst the drug 
metabolising enzymes. Approximately 40 % of all human CYP dependent metabolism is 
carried out by genetic polymorphic enzymes [6]. CYP2C9, CYP2C19 and CYP2D6 are the 
most important polymorphic enzymes, while no important genetically different forms have 
been found in CYP3A4 [6]. CYP2D6 is one of the best characterised and studied polymorphic 
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reticulum 
CYP
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drug metabolising enzymes.  As many as 70 allelic variants have so far been found for 
CYP2D6 [14]. Of these, more than 15 encode an inactive enzyme or no enzyme at all, while 
others encode enzyme with reduced, normal or increased activity. This genetic diversity 
divides people into 4 CYP2D6 phenotypic subpopulations of metabolisers; i.e. poor (PM), 
intermediate (IM), extensive (EM) and ultra rapid (UM). The frequencies of these phenotypes 
show a marked interethnic variability. In Caucasians, about 7 % are poor metabolisers, 
compared with only ∼1 % of Orientals [4, 14].  
 
CYP2D6 catalyses the metabolism of a quite large group of drugs, including antidepressants, 
antipsychotics, analgetics and cardiovascular drugs. For implicated drugs, individual 
differences in CYP2D6 phenotype can indeed lead to clinically significant variability in drug 
response. In general, CYP2D6 PMs are particularly susceptible to drug accumulation and 
adverse reactions, while ineffective therapy could be the outcome for CYP2D6 UMs. 
However, several aspects need to be taken into account, including pharmacological activity of 
metabolites and degree of metabolism via the polymorphic enzyme compared to other routes 
of elimination. Moreover, it has been shown that active metabolites could be substrates for 
polymorphic enzymes in contrast to the parent compound [15]. This implies that the parent 
drug might be pharmacologically unaffected by variability in metabolic phenotypes, but not 
its therapeutic response. The drug’s therapeutic index must also be considered with respect to 
the severity of genetic variability. Drugs with steep dose-response curves are more likely to 
cause adverse effects and drug toxicity. The complexity of this issue shows that the clinical 
impact of genetic polymorphism needs to be closely studied for each separate drug.  
   
1.3 STRATEGIES TO INVESTIGATE THE ROLE OF CYP ENZYMES 
IN DRUG METABOLISM 
 
Drug metabolism is one of the major determinants for the systemic drug exposure of many 
drugs. Thus, pharmaceutical industry has not surprisingly showed a growing awareness of the 
critical role drug metabolism constitutes in drug therapy. During drug development, the 
pharmaceutical companies now seek to obtain early information on human metabolic 
processes of new drug candidates [16]. This includes determination of metabolic pathways 
and identification of drug metabolising enzymes to predict the importance of polymorphic 
enzymes as well as potential drug interactions [12, 16]. Several in vitro enzyme systems have 
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emerged as a suitable tool at this stage of the process. Preclinical in vitro information on drug 
metabolism in humans can contribute to the design of the important pharmacokinetic and 
toxicological studies on animals in the early phase of drug development [16]. On a later stage, 
when the drug moves into phases of high-cost clinical studies, the in vitro data can give 
valuable contributions to the design of these studies (e.g. genetic and drug interaction studies).  
 
Two major approaches can be used to study the in vitro metabolic profile of a drug: 
• Incubate the drug with differentiated cellular models, such as isolated and  
 cultured hepatocytes or liver tissue slices. 
• Incubate the drug with subcellular fractions of endoplasmic reticulum  
 (microsomes).    
 
Hepatocytes are unique in that they provide a cellular integrity with intact enzyme 
architecture, membrane and phase II metabolism. They are thereby the closest model for 
reflecting the in vivo situation of many xenobiotics. However, this model involves transport of 
the substrate across the cell membrane, which may affect the exposure of the substrate or the 
inhibitor to the metabolising enzymes. A major drawback with primary hepatocyte cultures is 
their lack of ability to grow in vitro. As a consequence,  these must be prepared from suitable 
liver tissue (biopsies) each time they are used [12, 17, 18]. 
 
Microsomes are produced by differential centrifugation of liver cells. Human liver 
microsomes (HLM) are also commercially available. Studies with HLM are primarily 
performed with a pool of microsomes from several donors. This eliminates the important 
issue of inter-individual variability. Microsomes perform rapid metabolism, they are easy to 
use and can be stored at -80° C for a longer period without lack of activity. Although 
microsomes have become the most frequently used model to determine in vitro drug 
metabolism, there is still a need for standardisation of the procedures used. Differences in 
incubation conditions or substrate concentrations make it difficult to compare and validate 
studies that investigate metabolism of similar compounds [19]. 
 
When the metabolic profile of a drug has been described, the following strategies are 
frequently applied to identify the CYP enzyme(s) responsible for a particular metabolic 
reaction: 
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• Co-incubate the drug with HLM in absence and presence of selective and potent 
 CYP inhibitors. 
• Incubate the drug with recombinant enzyme systems, which have been genetically 
 manipulated to express only one single CYP enzyme (either cultured cells or 
 microsomes isolated from such cells).  
 
Often, these two approaches are combined to confirm the importance of a particular enzyme 
in a certain metabolic reaction of a drug. 
 
1.4 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-MASS 
SPECTROMETRY- AN IMPORTANT TOOL IN METABOLITE 
IDENTIFICATION  
 
Drug metabolism studies require highly sensitive analytical methods. High performance 
liquid chromatography coupled to mass spectrometry, HPLC-MS, has become the most 
suitable procedure for such studies [20]. HPLC-MS is widely used in both qualitative and 
quantitative analysis in research and drug development [21]. MS is a highly sensitive detector, 
but the major advantage is that it enables both mass-specific (single-MS) as well as structural 
(tandem-MS) information. Thus, metabolites for which no reference compounds exist can be 
identified with a high degree of certainty. Continuous improvements in this technology have 
made it applicable to almost every analyte. Low detection limits (pico-level), short run time, 
high specificity, precision and accuracy are some of its many advantages [22]. 
 
1.4.1 INSTRUMENTATION  
A mass spectrometer separates charged atoms or molecules according to their mass-to-charge 
ratio (m/z). The instrument consists of an inlet system (here: chromatographic), ion source, 
capillary, skimmers and lenses, mass analyser and an ion detector (Fig. 1-2). The most 
important step in mass spectrometry is the ionisation procedure, as it is the charge that makes 
it possible to select individual ions and measure their mass. A sample can be introduced into 
the ion source via several different ionisation techniques. Atmospheric pressure ionisation 
(API) techniques, such as chemical ionisation (CI) and electrospray (ESI), are ideal to 
combine with liquid chromatography. 
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Fig. 1-2: Schematic presentation of the instrumentation in MS [22]. 
 
In ESI, the HPLC eluent is pumped through a capillary, which carries a high potential. The 
potential together with a nebulising gas cause the solvent to break into charged droplets of 
one polarity. A hot drying gas makes the droplets evaporate and a vacuum system accelerates 
the ions towards the analyser region. In APCI, ionisation is achieved by the use of an ionised, 
heated reagent gas like methane or ammonia that forces charges onto the molecules. This 
latter technique tends to have an advantage for less polar, thermally stabile compounds. For 
both techniques, it is of great importance that mobile phases and buffers used are volatile. Salt 
formation in the ion source and clotting of the capillary can occur if unsuitable solvents are 
used. A potential problem in HPLC-MS analysis is the formation of adduct ions like 
[M+NH4]+ or [M+Na]+ in addition to the preferred molecule ion [M+H]+. Adduct ions could 
be formed even if the mobile phase does not contain the ions. Simply placing analytes in glass 
bottles or glass auto-sampler vials extract trace quantities of sodium ions and can lead to 
formation of undesirable adducts. Multiple ionic forms of the analytes are undesirable due to 
loss of sensitivity and reproducibility.  This problem can be overcome by adding a HPLC 
mobile phase additive that will favour the formation of a single, major molecular ion [22, 23].  
 
1.5 CHARACTERISTICS OF SIMVASTATIN 
 
1.5.1 PHYSICAL/CHEMICAL DATA 
• Formula: C25H28O5 
• Chemical name: Butanoic acid, 2,2-dimethyl-1S,3R,7S,8S,8aR-1,2,3,7,8a-
hexahydro- 3,7-dimethyl-8-[2-[2R,4R)tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl] 
ethyl]-1-naphtalenyl ester 
• White, crystalline, non-hygroscopic solid 
Inlet system 
Ion source 
Capillary Skimmers and lenses
Mass analyser
Ion detector 
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• Solubility: insoluble in water (0,03mg/ml), soluble in polar, organic solvents 
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Fig.1-3: Chemical structure of simvastatin 
 
 
1.5.2 CLINICAL USE  
Simvastatin (Fig. 1-3) is a HMG-CoA reductase inhibitor (statin), widely used in the 
treatment of hypercholesterolemia. The consumption of statins in Norway have increased 
steeply since 1994, and the sales increased threefold from 1997 to 2002, measured in number 
of sold DDDs (defined daily dose) (Fig. 1-4).  Simvastatin and atorvastatin were number one 
and two on the list of top-selling prescription only medicines in Norway in 2002,  and statins 
as a group constituted 8 % of the total sales [24].   
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Fig. 1-4: Sales of serum lipid reducing agents in Norway in the period 1988 – 2002 [24]. 
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This explosive increase in consumption must be seen in connection with several major 
placebo controlled clinical trials that have been performed with statins since 1994 [25-29]. 
Together, these have demonstrated the efficacy of statin treatment in reducing the risk of 
coronary heart disease (CHD) events, the leading cause of deaths in industrialized countries. 
Statins have shown a reduction in the relative risk of myocardial infarction and CHD events 
by 23-37 % in primary as well as secondary prevention therapy [30]. Recent evidence 
suggests that more aggressive LDL-cholesterol lowering may provide greater clinical 
benefits, even for individuals with moderately elevated or average lipid level [31].   
 
1.5.3 MODE OF ACTION AND TOLERABILITY 
Simvastatin lowers cholesterol by inhibition of the enzyme 3-hydroxy-3-methylglutaryl 
coenzyme (HMG-CoA) reductase, which catalyses the rate limiting step in cholesterol 
biosynthesis in the body. This effectively reduces the cholesterol synthesis and leads to an up-
regulation of cell surface low density lipoprotein receptors and subsequent decreased level of 
LDL-cholesterol [32]. Currently, there are 5 statins on the norwegian market; lovastatin 
(Mevacor), simvastatin (Zocor), pravastatin (Pravachol), fluvastatin (Lescol) and 
atorvastatin (Lipitor) [33]. As a group, the statins are generally well tolerated. However, 
muscle abnormalities may occur .These can range from benign myalgia to myopathy (ten fold 
elevation in creatin kinase level) which can further progress to the life threatening condition 
rhabdomyolysis [32, 34]. The statin cerivastatin (Lipobay) was withdrawn from the market 
in 2001 because of high frequency of serious myopathy and rhabdomyolysis [35]. When using 
statins in monotherapy the incidence of myopathy and rhabdomyolysis are approximately 0,1-
0,5 % and 0,04-0,25 %, respectively. The incidence of these side effects show dose 
dependence and is increased when SV is concomitantly administered with other agents that 
can cause muscle toxicity (e.g. fibric acid derivates) or agents that are potential inhibitors of 
statin metabolism [31, 34, 36]. Statins are in most cases prescribed on a long-term basis, and 
many patients will typically receive multi-drug treatment (polypharmacy) during this periode. 
Thus, possible interactions with other drugs deserve high attention.  
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1.5.4 METABOLISM  
With the exception of simvastatin (SV) and lovastatin (LV), all current statins are 
administrated as the active β-hydroxy acid form. SV and LV are administered as inactive 
lactone prodrugs and must be hydrolysed in vivo to their corresponding, pharmacologically 
active β-hydroxy acid forms [1, 37]. The absorption of simvastatin is approximately 60-80%, 
while bioavailability is only 5 % [38]. This low systemic bioavaliability is due to the high 
degree of  presystemic metabolism. Several in vivo and in vitro studies [39-41] have shown 
that SV undergoes extensive metabolism to several hydroxylated metabolites, as well as 
hydrolysis of the lactone ring to yield the active open acid form. Among these, simvastatin 
acid (SVA) is probably the most potent inhibitor of HMG-CoA reductase, but some of the 
oxidative metabolites are also active in their acidic forms [32, 40, 41].  
 
A metabolic pattern of SV was proposed in 1990 by Vickers et al. through studies with 
rat/mice liver microsomes and human bile extract [41]. Four major metabolites were formed 
upon incubation with rat and mice microsomes (6`-OH-SV which was rearranged to 3´-OH-
SV upon acidic conditions, 3``-OH-SV, 6-exomethylen-SV and SVA). In addition, two other 
metabolites, 6´-CH2OH-SV and 6´-COOH-SV were found in human bile (Fig. 1-5).  The two 
biliary metabolites, were found to have approximately 90 and 40 % HMG-CoA reductase 
inhibitory activity, respectively (compared to SVA) [41]. Later, Prueksaritanont et al. 
described another metabolite, 3´,5´-dihydrodiol-SV, in studies with SV and HLM [1]. In this 
latter study, four major oxidative metabolites were observed (Fig. 1-6). 
    
CYP3A4 is importantly involved in the oxidatations of SV indicated in Fig. 1-6 [1], but there 
is limited data on the enzymes further catalysing the active metabolites or alternative 
metabolic pathways. In a recent publication, Prueksaritanont et al. reported that metabolism 
of SVA is also mediated by CYP3A4 [42]. However, it was observed that SVA was a much 
poorer substrate for CYP3A4 enzymes than SV lactone [42].  
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Fig. 1-5: Structures of in vitro and in vivo metabolites of SV.Major in vitro metabolites were 6`-OH-SV 
(rearranged to 3`-OH-SV upon acidic conditions), 3``-OH-SV, 6-exomethylen-SV and SVA. These were 
obtained by incubations with liver microsomes from rats and mice. Biliary metabolites (in human) also included 
6`CH2OH-SV  and 6`COOH-SV [41]. 
 
 
3´´OH-SV 6´-OH-SV 
3´-OH-SV 
6-exomethylene-SV SVA 
6´-CH2OH-SV 6´-COOH-SV 
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Fig. 1-6: Major metabolites observed in incubation of SV with HLM by Prueksaritanont et al [1].  
 
 
Although CYP2D6 has been shown not to be involved in the reactions described in Fig. 1-6, 
clinical studies have recently suggested a possible involvement of CYP2D6 in the metabolism 
of SV. Nordin et al. [3] found that cholesterol in serum during treatment with 40 mg SV 
correlated negatively with debrisoquine ratio, which is an in vivo probe for CYP 2D6 activity 
(Fig. 1-7). However, none of the 8 healthy volunteers in the study were CYP2D6 PMs. 
Similar observations were reported by Mulder et al. [2, 43, 44], who found a significantly 
higher cholesterol reduction per mg administered dose in CYP2D6 PMs compared to EMs 
(Table 1-1). In addition, 80 % of the PMs had to discontinue the therapy because of adverse 
events, whereas one patient with UM phenotype showed a very low cholesterol reduction 
even at a daily dose of 40 mg SV. 
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Fig.1-7: Cholesterol in serum after simvastatin treatment [3]. * Fasting serum cholesterol concentration during 
SV treatment, expressed as % of pre-treatment concentration. 
 
Table 1-1: Association of CYP2D6 phenotype and efficacy per dose SV administered and intolerability of SV 
treatment in 88 patients with hypercholesterolemia [2]. 
 
Based on these clinical results, the authors speculated that one or more of the active 
metabolites of SV is metabolised by the polymorphic CYP2D6 enzyme. Lack of 
pharmacokinetic measurements in the referred studies prohibited a verifiation of this 
assumption. The fact that another group, Geisel et al., claim that they did not find an 
assosiation between SV effect and CYP2D6 phenotype in a third, unpublished study [43], 
implies that there is great uncertainity about the importance of CYP2D6 phenotype for the 
total pharmacological response of SV. In view of this uncertainity and the widespread use of 
this drug, the aim of present study was to investigate the possible role of CYP2D6 in SV 
metabolism, and in particular to clarify whether any of the SV metabolites are possible  
substrates for CYP2D6. 
PM = poor metabolisers 
HEM = heterozygous extensive metabolisers
EM = homozygous extensive metabolisers 
UM = ultra rapid metabolisers 
CYP2D6  
phenotype 
  
PM (n=5) 
 
HEM (n=28) 
 
EM (n=54) 
 
UM (n=1) 
Cholesterol reduction (mmol/L)
pr. mg simvastatin 
 
0,23 
 
0,20 
 
0,10 
 
0,01 
 Number of 
intolerants (%) 
 
80 
 
46 
 
17 
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   Debrisoquine/4-Hydroxydebrisoquine (urine 0-8h)
n=8, 40 mg simvastatin per. day (2 weeks) 
 
CYP2D6 PMs 
ratio > 12,4 
Relative  
S-cholesterol  
concentration * 
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 2. MATERIALS AND METHODS 
 
CHEMICALS  
 
Acetonitrile, HPLC grade      Chemi-Teknik A/S, Oslo, Norway 
Acetic acid, glacial, analytical grade     Chemi-Teknik A/S, Oslo, Norway 
Acetone, HPLC grade      Chemi-Teknik A/S, Oslo, Norway 
B-nicotinamid adenine dinucleotide- 
phosphate reduced tetrasodium salt (NADPH)  SIGMA, Steinheld, Germany  
Cis (+)-desacetyldiltiazem HCl     Tanabe Seyaku, Osaka, Japan 
Deionised water (19,3 MΩ-cm) Easypure UV, Barnstead, Iowa, 
USA 
Formic acid, analytical grade      MERCK, Darmstadt, Germany 
Erythromycin       SIGMA, Steinheld, Germany 
Lovastatin       MERCK, Rahway NJ, USA 
Magnesium sulphate, analytical grade   MERCK, Darmstadt, Germany 
Methanol, HPLC grade     Chemi-Teknik A/S, Oslo, Norway 
Methylamine 40%, analytical grade    Chemi-Teknik A/S, Oslo, Norway 
Nitrogen gas       AGA Progas A/S, Oslo, Norway 
Simvastatin       MERCK, Rahway NJ, USA 
Sulphuric acid, analytical grade    MERCK, Darmstadt, Germany 
Tris (hydroxymethyl) aminomethane   Chemi-Teknik A/S, Oslo, Norway 
Quinidine hydrochloride monohydrate   SIGMA, Steinheld, Germany 
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2.1 IN VITRO METABOLISM OF SIMVASTATIN 
 
2.1.1 STUDIES WITH HUMAN LIVER MICROSOMES 
HLM, (20 mg protein/ml) pooled from 50 subjects were purchased from In Vitro 
Technologies, Baltimore, USA. These were stored in liquid nitrogen (-196° C) and carefully 
thawed on ice before use. The incubation reaction was carried out in 2 ml eppendorf vials 
with a safe sealing, and incubation conditions were chosen on the basis of a previous master 
thesis by Eili T. Kase [18]. A typical incubation mixture in a final volume of 500 µl contained 
389 µl 200 mM Tris-H2SO4 buffer (pH 7,5), 78 µl 10 mM NADPH (dissolved in  200 mM 
Tris-H2SO4 buffer), 15 µl HLM and 13 µl 20 mM MgSO4 (dissolved in sterile water). SV was 
pre-dissolved in acetone [41] and added to the incubation mixture to a final concentration of 
100 µM. Acetone concentration in the final incubate did not exceed 1%. The reaction 
mixtures were incubated for 10 and 60 minutes at 37° C in a Fermaks incubator with a Vari-
mix Thermolyne (Dan Meszansky A/S, Oslo, Norway).  
 
Incubations were performed in absence (i.e. control) and presence of potent inhibitors of 
CYP3A4 (erythromycin 10 and 100 µM) and CYP2D6 (quinidine 5 and 25 µM). All 
experiments were carried out with 4 parallels at each experimental condition.  In the 
experiments with erythromycin, the inhibitor was pre-incubated with HLM and NADPH for 
30 minutes at 37° C (to obtain metabolite complexation) before adding SV in Tris-buffer and 
MgSO4.  The non-competitive inhibitor, quinidine, was co-incubated with the substrate. 
Incubations were terminated after 10 or 60 minutes by the addition of 1 ml acetonitrile (4° C). 
After 10 minutes on ice, the vials were centrifuged on a Universal 32R centrifuge (Hettich 
zentrifugen, Tuttlingen, Germany) for 15 minutes at 14000 rpm. To exclude separation of 
organic and aqueous phases, the whole supernatant was transferred to a new eppendorf vial 
and mixed for 10 seconds on a MS 1 Minishaker (Heigar laboratorieutstyr, Oslo, Norway). 
Then, 500 µl of the supernatant was mixed with 50 µl of internal standard solution (lovastatin 
(LV), 100 µg/ml, dissolved in acetonitrile) and subsequently evaporated to dryness by 
nitrogen gas. The residue was redissolved in 120 µl mobile phase A (20 % acetonitrile, 80% 
methylamine buffer, see section 2.3). This solution was centrifuged once more for 10 minutes 
at 14000 rpm, and 100 µl of the supernatant was finally injected onto the HPLC-MS system.   
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2.1.2 STUDIES WITH RECOMBINANT CYP ENZYMES 
Recombinant human liver epithelial cell lines with specific expression of CYP3A4 (T5-3A4) 
and CYP2D6 (T5-2D6) were provided from the Nestlé Research Centre, Lausanne, 
Switzerland. Microsomal fractions from these cells were prepared according to the method 
described in the previous master thesis by Eili T. Kase [18]. The microsomes from these 
recombinant enzyme systems were used in an experimental procedure where the purpose was 
to study a possible CYP2D6 mediated, subsequent metabolism of SV metabolites following 
production via CYP3A4 microsomes. Incubations were performed with the same conditions 
as described in section 2.1.1, with minor modifications (see below).  A schematic presentation 
of the incubation procedure used is illustrated in figure 2-1. First, 100 µM SV was incubated 
with T5-3A4 microsomes for 60 minutes. After termination of the reaction and removal of the 
proteins, one third of the supernatant was evaporated and reconstituted for analysis by HPLC-
MS (see section 2.2), whereas another third part was re-incubated with T5-2D6 microsomes 
for 60 minutes. The supernatant from this latter incubation was also analysed by HPLC-MS, 
and the resulting metabolite pattern was compared with that found after incubation with T5-
3A4. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
      
          
Fig. 2-1: Schematic presentation of the procedure used to study the sequential metabolism via CYP3A4 and 
CYP2D6 in microsomes from T5-3A4 and T5-2D6 recombinant cells. 
100 µM SV
+ T5-3A4 
Incubation: 
60 minutes at 37° C.
Reaction termination and centrifugation
 
     1/3  1/3           
HPLC/MS analysis
Incubation: 
60 minutes at 37° C.
HPLC/MS analysis 
+ T5-2D6 
Reaction termination and centrifugation  
To waste 
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The incubation mixture contained 112 µl  T5-3A4 microsome suspension in a total volume of 
500 µl (=0,67-0,87 mg protein/ml). The amount of Tris-H2SO4 buffer was accordingly 
reduced to 292 µl. The reaction was started by the addition of 112 µl T5-3A4 microsomes 
following a 3 minutes pre-incubation at 37° C of the substrate, NADPH and MgSO4. After 
termination of the reaction and removal of proteins (section 2.1.1), 500 µl of the supernatant 
was added 50 µl I.S, evaporated to dryness, resolved in mobile phase A and analysed by 
HPLC-MS. Another 500 µl part of the supernatant was also evaporated to dryness. To the 
residue 39 µl NADPH and 155 µl sterile water was added. This solution was pre-incubated 
for 3 minutes at 37° C before addition of 56 µl T5-2D6 microsome suspension to a final 
volume of 250 µl (=0,67-0,87 mg protein/ml). The reaction was terminated after 60 minutes 
by the addition of 500 ml acetonitrile (4° C).  I.S. (50 µl) was added after 10 minutes on ice, 
and proteins were removed before the whole supernatant (~750 µl) was evaporated to dryness. 
The final residue was redissolved in 120 µl mobile phase A and injected onto the HPLC-MS 
system. 
 
In order to confirm the functionality of this procedure, a known substrate for CYP3A4 and 
CYP2D6, the diltiazem metabolite desacetyldiltiazem (M1), was incubated following the 
same procedure as for SV. It has earlier been shown that CYP2D6 and CYP3A4 are 
mediating the O-and N-demethylation of M1,  respectively (Fig. 2-2) [45]. The substrate 
concentration was 100 µM, and the samples were analysed as described by Molden et al. [46].   
 
 
    
 
 
                              
 
 
 
Fig. 2-2: Metabolic pathways of desacetyldiltiazem, M1[45]. Abbreviations used; M1=desacetyldiltiazem, 
M2=N-desmethyldesacetyldiltiazem, M4=O-desmethyldesacetyldiltiazem, M6= N, O-di-
desmethyldesacetyldiltiazem. 
 
 M2 M4
 M6
CYP2D6 
CYP2D6 
CYP3A4 
CYP3A4 
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2.2 DEVELOPMENT AND APPLICATION OF A HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY-MASS 
SPECTROMETRY ANALYSIS OF SIMVASTATIN AND ITS IN VITRO 
METABOLITES  
 
2.2.1 THE CHROMATOGRAPHIC SEPARATION  
The HPLC equipment (ThermoFinnigan, Austin, Texas, USA) consisted of an AS3000 
autosampler and a P4000 quaternary pump.  Aliquots (100 µl) of the samples were placed in 
the chilled autosampler tray (4° C). A reversed phase C18 column (Omnisphere C18, 30 x 2 
mm, 3 µm, Varian, Harbor City, CA, USA) was used for chromatographic separation of SV 
and its metabolites. The analytical column was preceded by a guard column (Chromguard, 10 
x 2 mm, 5 µm, Varian, Harbor City, CA, USA).  A linear gradient mobile phase system eluted 
the analytes, as illustrated in Fig. 2-3. Solution A consisted of a 20/80 (v/v) mixture of 
acetonitrile and 2 mM methylamine buffer (adjusted to pH 4.5 with glacial acetic acid), 
whereas solution B had the same components in a relationship 80/20. 
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Fig. 2-3:  The linear gradient system used for the chromatographic separation of SV and its metabolites. 
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The mobile phase changed from 100 % A to 100% B in 10 minutes. From 10 to 16 minutes of 
the run the mobile phase was 100 % B, then reversed to 100 % A over 17 seconds. The flow-
rate was set at 0.2 ml/min during the first 16.1 minutes. During the last 3 minutes of the run, 
the column was re-equilibrated with mobile phase A (with a flow-rate set at 0.4 ml/min) 
before injection of another sample. The total run time was 19 minutes per sample. During the 
first 2 and last 3 minutes of the run the flow was sent to waste.   
 
2.2.2 MASS SPECTROMETRIC DETECTION 
The HPLC equipment was coupled to a ThermoQuest LCQDUO ion trap MS detector 
(ThermoFinnigan, Austin, Texas, USA), and the HPLC-MS interface was operated with an 
electrospray (ESI) inlet. The analysis was performed in positive mode (ESI+).  Tuning of the 
detector and optimisation of the ESI conditions were performed by injection of SV in mobile 
phase B (1000 ng/ml). A summary of the MS conditions used in the analysis of SV and 
metabolites is shown in appendix 1. 
 
The detector was operated in single-MS, full scan mode. In the initial phase of the analytical 
method development, 1 mM formic acid was added to the mobile phase to improve sensitivity 
in the positive-ion mode. However, formation of various adduct ions of SV and metabolites, 
such as [M+Na]+  and [M+NH4]+ was not optimal. Zhao et al. have investigated the effects of 
ammonium and various different alkylammonium acetate as mobile phase additives on the 
ionisation of SV and SVA [23] and observed that methylammonium acetate significantly 
improved the ion signal intensity of SV.  By adding this buffer to the mobile phase system  
the methylammonium adduct of SV, [SV+CH3NH3]+, was observed as the only major 
molecule ion, while the formation of other adduct ions were successfully suppressed. Thus, it 
was decided to add methylamine buffer (2mM, pH 4.5) to the mobile phase in the further 
development.  
 
With methylamine as a mobile phase additive methylammonium adduct ions, [M+CH3NH3]+ 
of both SV, I.S. and possible in vitro metabolites were expected to be the major ions in the 
full scan spectra. Due to lack of reference compounds, SV metabolites were deduced from 
MS peaks that showed a clear increase in intensity by incubation time. Their structural nature 
was interpreted from the characteristic mass-to-charge ratios of the detected peaks and their 
chromatographic retention times.    
 
  Materials and methods 
 
27
2.2.3 EVALUATION OF METHOD PRECISION 
A large batch of quality control (q.c) samples, containing 5 µg/ml SV and 5 µg/ml I.S 
dissolved in mobile phase A, was prepared to evaluate inter- and intra assay variability in 
analytical precision. These samples were stored at -20° C, and two parallels were included in 
each analytical run (first and final analysis of each experiment). 
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3.  RESULTS AND DISCUSSION 
 
3.1 IN VITRO METABOLISM OF SIMVASTATIN 
 
3.1.1 STUDIES WITH HLM IN ABSENCE OF INHIBITORS. 
Fig. 3-1 illustrates a typical ESI–single-MS chromatogram derived from incubates of HLM 
with SV in absence of CYP inhibitors. SV lactone was eluted ~12.1 minutes after sample 
injection, whereas its corresponding hydroxy acid (SVA) was eluted at ~9.6 minutes. The 
retention time of the I.S (lovastatin) was ~11.3 and ~8.9 minutes for the lactone and acid 
form, respectively.  
 
Reference compounds of SV metabolites were not available. However, based on mass-
specific detection and chromatographic features, five MS peaks were interpreted to be lactone 
metabolites of SV (denoted I-V in Fig. 3-1).  The m/z values present in the five MS peaks and 
the corresponding m/z values of the hydroxy acid forms (formed by non-enzymatic 
hydrolysis), are shown in Table 3-1. Except for metabolite 6´-COOH-SV (V), the 
corresponding hydroxy acid form of these lactone metabolites was apparent in the spectra 
(denoted IA-IVA in Fig. 3-1). In the further presentation, denominations and values of the 
metabolites I-V include both the lactone and acid forms.  
 
Table 3-1: SV, I.S. and SV metabolites (I-V) present in HLM incubates, with corresponding masses (m/z) of 
their methylamine adduct, [M+CH3NH3] +. Incubations were carried out as described in 2.1.1, in absence of 
inhibitors. 
      COMPOUND                                           LACTONE (m/z)                    ACID (m/z) 
SV 450 468 
I.S. 436 454 
6´-CH2OH-SV (I) 466 484 
3´-OH-SV (II) 466 484 
6´-exomethylene-SV (III) 448 466 
3´-OH-6´-CH2OH-SV (IV)  482 500 
6´-COOH-SV (V) 480 498 
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Fig. 3-1: A representative ESI-single MS chromatogram of SV and metabolites in a HLM incubate, presented as 
total ion current (sum of all compounds detected) and m/z-selected, individual chromatographic spectra of SV, 
I.S. and SV metabolites Structures of SV and the proposed metabolites I-V are presented in the figure. 
Incubations were carried out as described in 2.1.1, in absence of inhibitors.  
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The increased signal intensities of all the deduced metabolites (I-V) with time in HLM 
incubations provided further evidence that these compounds were metabolites of SV (Fig. 3-
2). Correspondingly, the level of SV declined by 44 % from 10 to 60 minutes of incubation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-2: Effect of incubation time on the relative levels of SV and deduced metabolites (I-V) in the HLM 
incubates. Values are presented as mean (n=4) ratios of the MS-signal intensities after 10 and 60 minutes 
incubation (ratio=MS peaks60min / peaks10min, i.e. ratio at 10 minutes=1 for all agents ). Incubations were carried 
out as described in 2.1.1, in absence of inhibitors.  
 
 
The presence of two closely eluted peaks both with m/z=466 (one major peak at ~7.9 min and 
one minor peak at ~8.5 min, Fig. 3-1) was interpreted as two distinct mono-hydroxylated 
lactone metabolites. As the metabolite 6´-COOH-SV (V) also was formed in HLM 
experiments, it is reasonable to believe that its reduced precursor, 6´-CH2OH-SV (I) 
represented one of the mono-hydroxylated metabolites. The other mono-hydroxylated 
metabolite was interpreted to be 3´-OH-SV (II), based on its presence in former HLM 
experiments with SV [1]. This latter metabolite will have a slightly longer retention time (i.e. 
less chromatographic retention on a reversed phase system) compared to 6´-CH2OH-SV (I), 
as seen in Fig. 3-1. The corresponding hydroxy acids of 6´-CH2OH-SV (I) and 3´-OH-SV 
were also seen as two peaks in the chromatographic spectra (~6.1 and ~6.3 min). 
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Previous in vitro studies with SV have not reported the metabolites 6´-CH2OH-SV (I) and 6´-
COOH-SV (V).  However, together with 3´-OH-SV (II), these metabolites are described to be 
the most abundant SV metabolites in human bile [41]. The HMG-CoA reductase inhibitory 
activity of the hydroxy acid form of these metabolites were examined by Vickers et al. [41].  
Compared to SVA, metabolite 6´-CH2OH-SV (I) and 6´-COOH-SV (V) showed 
approximately 90 % and 40 % inhibiting activity, respectively, whereas metabolite 3´-OH-SV 
(II) completely lacked inhibitory activity [41]. 
                                                                                                                                                                               
6´-Exomethylen-SV (III) eluted closely to SV lactone as expected from their structural 
similarities. The acid form, was interpreted to be the third peak with m/z=466 (IIIA, eluted at 
~9.4 min, Fig. 3-1). The di-hydroxylated SV metabolite, IV, is likely the combined metabolite 
of the two mono-hydroxylated metabolites, 6´-CH2OH-SV (I) and 3´-OH-SV (II), namely 3´-
OH-6´-CH2OH-SV (IV).  Previous metabolism studies with SV have not described this 
metabolite, but it might be similar to one of the unidentified in vivo metabolites reported in 
human bile [41]. The sequential HPLC retention times of the suggested metabolites correlated 
well with the chromatographic features of Vickers et al.[41], who characterised their in vitro 
and in vivo metabolites by comparing retention times with reference compounds.  
 
The dissimilarities in metabolite profile between the present HLM experiment and the 
findings of Prueksaritanont et al. (section 1.5.4) [1] are likely due to differences in assay 
conditions. A range of factors, including pH and ionic strength, influences CYP activities 
[17]. It has been reported that pH significantly affected the metabolite formation of 
cyclosporine via CYP3A4 [18]. While Prueksaritanont et al. performed their experiments 
with a sodium phosphate buffer at pH 7.4 [1], the present study was carried out with a Tris 
buffer at pH 7.5. In addition, it is unclear  whether magnesium should be added (and in which 
amount) to microsomal incubations mixtures as this cofactor could create unwanted kinetic 
artefacts [17]. Prueksaritanont et al. used a 20 fold-higher magnesium concentration 
compared to present study. Thus, although similar SV concentration (100 µM) was applied in 
the HLM studies, there are differences in the incubation conditions that may explain different 
metabolite profiles. In contrast to Prueksaritanont et al, who only described one of the three 
major human biliary metabolites (3´-OH-SV), all three human bile metabolites were found in 
the present work. It is therefore likely that the results provided here better reflect the in vivo 
situation than those of the previous study.    
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6´-CH2OH-SV (I) was the most abundant metabolite in the experiments (Table 3-2). The level 
of this metabolite was >3-fold higher than the other oxidative metabolites. It was observed 
that the metabolites hydroxylated in 3´-position (3´-OH-SV (II) and 3´-OH-6´-CH2OH-SV 
(IV)) appeared dominantly as hydroxy acid forms, in contrast to SV and the metabolites 6´-
CH2OH-SV (I) and 6´-exomethylene-SV (III), where the lactone forms were the predominant 
form (Table 3-2 and Fig. 3-1). A possible explanation is that hydroxylation in 3´-position 
could involve hydrogen binding between the 3´-OH-group and a hydroxyl group in the open 
acid form, a situation that would favour the hydroxy acid form over the closed lactone form.  
 
Table 3-2: Relative MS-peak intensities (sum of lactone and acid form) and lactone/acid ratios of the deduced 
SV metabolites in HLM incubate. The values for relative MS-peak intensities (mean ± SD, n=4) are presented as 
ratios of the most abundant metabolite, 6´-CH2OH-SV (I). Incubations were carried out as described in 2.1.1, in 
absence of inhibitors.  
 
SV metabolites Relative intensities   Lactone/acid ratio 
6´-CH2OH-SV (I) 1 2,3 ± 0,4 
3´-OH-SV (II) 0,15 ± 0,004  0,53 ± 0,2 
6´-exomethylen-SV (III) 0,32 ± 0,02 7,0 ± 0,4 
3´-OH-6´-CH2OH-SV (IV) 0,11 ± 0,03 0,56 ± 0,07 
6´-COOH-SV (V) 0,06 ± 0,03 only detected as lactone 
 
 
Altogether, four distinct oxidative modifications of SV were detected in the current HLM 
experiments. Based on these reactions, an oxidative metabolite pattern is proposed in Fig. 3-3, 
where 3´-OH-6´-exomethylene-SV (VI) and 3´-OH-6´-COOH-SV (VII) are outlined as end-
stage metabolites of the oxidative reactions. Trace amounts of 3´-OH-6´-exomethylene-SV 
(VI) appeared as a peak at ~8.2 min (not indicated in Fig. 3-1), but its peak intensity was too 
low to be detected with sufficient accuracy. The metabolite 3´-OH-6´-COOH-SV (VII) was 
not present in the MS chromatogram after incubations of SV with HLM. The absence of this 
metabolite probably reflected that it is too hydrophilic to be detected in the present mobile 
phase system (eluted in the front).   
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Fig. 3-3: Proposed metabolite pattern of SV. The numbers 1-4 represent the four distinct oxidative modifications 
detected in the HLM experiments. R1 and R2, see Fig. 3-1. 
 
3.1.2 STUDIES WITH HLM IN PRESENCE OF INHIBITORS 
The CYP3A4 inhibitor erythromycin inhibited SV metabolism, in accordance with previous 
experiments [1]. SV level increased by 20-70 % (ratio 1,2-1,7 ) in presence of erythromycin, 
and this inhibition was dose-dependent (Fig. 3-4). Additionally, the inhibition of SV 
metabolism increased with time (Fig. 3-4). This agrees with the fact that erythromycin 
performs inhibition through metabolite complexation [47], which is a time dependent event 
(i.e. inhibitory effect increased with time).  
 
The level of the metabolites 3´-OH-SV (II) and 6´-exomethylen-SV (III) showed a small 
decline in presence of erythromycin (Fig. 3-4), also in agreement with previous in vitro study 
[1]. Likewise, the previously not reported metabolite 3´-OH-6´-CH2OH-SV (IV) followed the 
same pattern as its precursor 3´-OH-SV (II) in presence of erythromycin. The decline 
observed for 3´-OH-SV (II), 6´-exomethylene-SV (III) and 3´-OH-6´-CH2OH-SV (IV) was 
dose-dependent within both incubation times applied (10 and 60 min, Fig. 3-4). Based on the 
increased inhibition of SV metabolism with time, it was expected that the level of SV  
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Fig. 3-4: Effect of CYP inhibitors on the levels of  SV and metabolites in HLM incubations at different time 
events and inhibitor concentrations. SV metabolites are expressed as ratio of control activities (i.e. in absence 
of inhibitors).  The dashed line at y=1 represents the control activities. E= erythromycin (10/100µM), filled 
symbols, Q= quinidine (5/25 µM), open symbols. Results are presented as mean (n=4). SD is shown as + SD 
for values <1 and – SD for values >1. All incubations were carried out as described in section 2.1.1. 
(*) not detected.  
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metabolites would  decrease with time during co-incubations of erythromycin. It was 
observed that the level of the metabolites 3´-OH-SV (II), 6´-exomethylene-SV (III) and 3´-
OH-6´-CH2OH-SV (IV) actually was relatively higher at 60 minutes compared to 10 minutes 
incubation. The reason(s) for this observation is unclear, but it might perhaps indicate that the 
further metabolism of SV metabolites is catalysed via CYP3A4 to a higher degree than SV 
itself.    
 
The level of the most abundant metabolite, 6´-CH2OH-SV (I) increased with 10-20 % (ratio 
1,1-1,2) in presence of erythromycin (Fig. 3-4). This observation might indicate that 6´-
CH2OH-SV (I) is a better CYP3A4-substrate than its precursor SV or alternatively, that other 
enzymes than CYP3A4 are important in catalysing the formation of 6´-CH2OH-SV (I). The 
metabolite 6´-COOH-SV (V), the likely subsequent metabolite of 6´-CH2OH-SV (I), showed 
the relatively largest decline amongst the measured compounds in presence of erythromycin 
(Fig. 3-4). Incubation with 100 µM erythromycin for 10 minutes resulted in undetectable 
amounts of this metabolite, whereas the other conditions showed a decline of 40-70 % (ratio 
0,6-0,3) compared to control. As for 3´-OH-SV (II), 6´-exomethylene-SV (III) and 3´-OH-6´-
CH2OH-SV (IV), the relative level of 6´-COOH-SV (V) was higher after 60 minutes 
compared to 10 minutes of incubation. 
 
Co-incubation of quinidine, known as a potent inhibitor of CYP2D6, generally increased the 
level of all measured compounds compared to control (increase in 19 of 24 experimental 
conditions, Fig. 3-4). In contrast to erythromycin, quinidine did not demonstrate a dose 
dependent effect on SV and metabolites. A possible explanation is that quinidine performs 
100 % inhibition of CYP2D6 even at 5 µM, hence, adding more quinidine will not affect the 
degree of inhibition. The time dependent effect of inhibition seen with erythromycin was not 
observed for quinidine (Fig. 3-4). This is likely due to the fact that erythromycin and 
quinidines mediates different type of inhibition mechanisms. Quinidine is a non-competitive 
inhibitor [48] where inhibition is independent of time. 
 
Unlike the studies with erythromycin, none of the measured metabolites decreased in 
presence of quinidine. Based on these observations, it could be speculated that CYP2D6 
catalyses a common, unexplored, metabolic pathway of both SV and metabolites, not detected 
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in present work. It is possible that this presumed oxidation by CYP2D6 leads to a structural 
alteration, where the resulting products would not be detected under the applied MS 
conditions. Alternatively, the reaction could imply an increase in hydrophilicity, which leads 
to elution of the CYP2D6 mediated metabolites before the flow is directed to the MS detector. 
 
3.1.3 STUDIES WITH RECOMBINANT CYP ENZYMES 
In view of the speculations that one or more of the active metabolites of SV is metabolised by 
CYP2D6 [2, 3], an experiment was performed where SV first was subjected to CYP3A4 
metabolism (T5-3A4), and then the remaining SV and metabolites produced by T5-3A4 were 
subjected to further metabolism with T5-2D6 microsomes.   
 
Incubation of SV with T5-3A4 resulted in formation of 6´-CH2OH-SV (I), 3´-OH-SV (II) and 
6´-exomethylen-SV (III), but the two secondary metabolites, 3´-OH-6´-CH2OH-SV (IV) and 
6´-COOH-SV (V) were not detected. This was probably due to the relatively low formation of 
the precursors 6´-CH2OH-SV (I) and 3-OH-SV (II) in T5-3A4 incubations (10 fold lower than 
in HLM). Ratios of the three metabolites formed after incubation with T5-3A4 microsomes 
were compared with corresponding ratios of metabolites formed after incubation with HLM 
(Table 3-3). This was performed to evaluate the relative importance of CYP3A4 activity for 
the levels of the primary metabolites formed in the HLM experiments described in section 
3.1.1.  The higher relative levels of 6´-CH2OH-SV (I) and 6´-exomethylen-SV (III) compared 
to 3´-OH-SV (II) in HLM versus T5-3A4 experiments might indicate that these former 
metabolites are produced to a greater extent through non-CYP3A4 metabolism than 3´-OH-
SV (II). The analogous proportions of metabolite 6´-CH2OH-SV (I) and 6´-exomethylen-SV 
(III) in both the HLM and the T5-3A4 incubate, could reflect that these two metabolites 
follow identical enzymekinetic profiles.  
 
Table 3-3: Comparison of SV metabolite ratios in HLM and T5-3A4 incubates. The values are presented as 
mean ± SD (n=4). I= 6´-CH2OH-SV, II= 3´-OH-SV, III= 6´-exomethylen SV. 
 
Metabolite ratio                              HLM                                     T5-3A4 
 
I/II                                              6,8 ± 0,2 4,8 ± 2,1  
I/III                                             3,2 ± 0,2 3,2 ± 0,4  
III/II                                            2,2 ± 0,2 1,5 ± 0,7  
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In the combined experiment with T5-3A4 and T5-2D6 microsomes it was observed a slight 
decrease (~10%) in SV level after incubation with T5-2D6 compared to the level measured 
after incubation with T5-3A4, while the metabolites 6´-CH2OH-SV (I), 3´-OH-SV (II) and 6-
exomethylen-SV (III) was reduced by about 30, 15 and 30 %, respectively (Fig. 3-5). This 
decrease in all detected compounds upon incubation with T5-2D6 further supports that 
CYP2D6 is involved in the metabolism of SV and metabolites. However, the final end-stages 
of these metabolic reactions have not been determined in this study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3-5: Relative levels (ratios) of SV and metabolites after T5-2D6 incubation compared to level after T5-3A4 
incubation. The dashed line at y=1 represents the levels after incubation with T5-3A4. Results are presented as 
mean ± SD (n=4). Incubations were carried out as described in section 2.1.2.  
 
The functionality of the procedure used to study the sequential SV metabolism by T5-3A4 
and T5-2D6 microsomes was verified by the performance of an analogous experiment with 
the metabolite of the calcium-channel blocker diltiazem, desacetyldiltiazem, M1. After 
incubation with T5-3A4, the N-demethylated metabolite M2 was the only metabolite detected 
in the resulting MS chromatogram (Fig. 3-6A). During subsequent T5-2D6 experiments, M1 
was transformed to the O-demethylated metabolite M4, whereas M2 was converted to the N, 
O-didesmethylated metabolite M6 (Fig. 3-6B). This was in agreement with the expected 
metabolite profile illustrated in Fig. 2-2 (section 2.1.2). The level of the primary substrate, 
desacetyl-diltiazem (M1) and its CYP3A4 mediated metabolite, N-desmethyldesacetyl-
diltiazem (M2), decreased by about 35 and 70 %, respectively, after incubation with T5-2D6 
0,2
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(data not shown). These findings indicate that the procedure used in the studies with SV and 
recombinant CYP enzymes was suitable for its purpose.  
Fig. 3-6: MS chromatogram after incubation of M1 with T5-3A4 microsomes (A) and subsequently with T5-
2D6 microsomes (B). Incubations were carried out as described in section 2.1.2.  Abbreviations used; 
M1=desacetyldiltiazem, M2=N-desmethyldesacetyldiltiazem,M4=O-desmethyldesacetyldiltiazem, M6= N,O-di-
desmethyldesacetyldiltiazem. 
 
 
 
3.2 ANALYTICAL CONSIDERATIONS 
 
The initial use of 1 mM formic acid as a mobile phase additive resulted in multiple adduct 
formation. This unfavourable situation was significantly improved by the addition of 2 mM 
methylamine to the mobile phase, as 98 % of the total ion signal for SV was observed as 
methylamine adduct [SV +CH3NH3] + (Table 3-4).   
 
Due to lack of reference compounds of SV metabolites, a complete validation of the present 
HPLC-MS method could not be accomplished. The injection of a quality control (q.c.) sample 
of SV and I.S. as the first and final sample of each analytical run was performed to monitor 
possible variability in the MS detection. Table 3-5 summarises the intra- and inter-run 
variability of the q.c. samples analysed (6 runs, 12 q.c. samples). The degree of variation was 
   I. S (codeine) I.S. (codeine) 
A) T5-3A4 incubate: B) T5-2D6 incubate: 
M2 
M4 
M2 
M1 
M1 
M6 
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less than 10 %, except from one run where the intra- and inter-run was 11.9 % and 19.2 %, 
respectively (Table 3-5). These data were considered as satisfactory, and the analytical 
method developed in the present work is therefore suitable for in vitro metabolic studies. 
 
Table 3-4: Evaluation of the effect of different mobile phase additives on SV adduct formation. The adducts are 
expressed as % of the total ion current signal.  (*) rearranged from lactone to acid form in the ion source 
 
 
Adduct  Formic acid additive, 1 mM Methylamine additive, 2 mM 
 [SV+H ]+ 5 % 0,04 % 
 [SV+Na]]+ 10 % 0,08 % 
 [SV+NH4]+ 69 % 0 
 [ SV+ CH3NH3]+ 0 98 % 
 [SVA+H]+    * 15 % 0 
 
  
 
Table 3-5: Evaluation of the analytical variability. Data are presented as relative MS-peak intensities of SV in 
q.c. samples in 6 runs (n=2 in each run).  
 
Intra-run variability=   p1-p2      * 100 %, Inter-run variability= mean tot – mean run * 100 % 
             p2               mean tot 
 
Run      Parallel          Rel. peak int.            Intra run variability (%)                    Inter run variability (%)  
1 1.1 0.887  2.0 5.0 
 1.2 0.869    
2 2.1 0.821  2.6 9.9 
 2.2 0.843    
3 3.1 0.915  0.51 1.2 
 3.2 0.910    
4 4.1 0.902  8.9 6.8 
 4.2 0.821    
5 5.1 1.171  11.9 19.2 
 5.2 1.032    
6 6.1 0.969  2.2 3.7 
 6.2 0.948    
 
 
 
Mean tot 0.924    
 
 
 
     
 
 
. 
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4. CONCLUSION 
 
 This is the first in vitro study with SV where all three major in vitro oxidative metabolites 
have been produced. The overall results of the conducted experiments indicate that CYP2D6 
is involved in the biotransformation of SV. Studies with the CYP2D6 inhibitor quinidine in 
HLM incubations and experiments with recombinant CYP enzymes suggested that CYP2D6 
might be responsible for a unknown metabolic reaction. However, the potential in vivo 
importance of CYP2D6 needs to be evaluated in a study where pharmacokinetic 
measurements of SV and metabolites are investigated in relation to CYP2D6 phenotype. 
Further in vitro experiments with analytical modifications should also be performed to 
identify the metabolic reaction possibly mediated by CYP2D6. 
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APPENDIX 
  
 MS LCQ Duo INSTRUMENT STATUS FOR THE ANALYSIS OF SV AND 
METABOLITES 
 
ESI Source: 
Spray voltage (kV)   :  4,5 
Spray current (µA)   :  1,37 
Sheat gas flow rate    :  20 
Aux gas flow rate   :  10 
Capillary voltage (V)   :  4 
Capillary temperature °C  :  200 
Tube lens (V, sp)   :  -5 
 
Ion optics: 
Multipole 1 offset (V)  :  -1,75 
Lens voltage (V)   :  -16 
Multipole 2 offset (V)  :  -7,5 
Multipole RF Amp (Vp-p, sp) :  400 
 
Ion detection system: 
Dynode voltage (kV)   :  -14,82 
Multiplier voltage (V)  :  -989,13 
 
 
 
 
 
 
 
 
 
